Smart wearable for monitoring bladder function in men with BPH
Official title: An Intelligent Wearable Device Based on Electrical Impedance Tomography for Dynamic and Accurate Monitoring of Voiding Function in Patients With Benign Prostatic Hyperplasia
Run by Peking University Third Hospital · NCT07357012 · Data updated 2026-11-12
A non-invasive wearable device is tested to see if it can measure bladder function as accurately as the standard uroflowmetry test in men with BPH.
Quick facts
| Study type | Observational |
|---|---|
| Sex | Men only |
| Enrollment | 40 (estimated) |
| Sponsor | Peking University Third Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Beijing, HaiDian and 1 other locations) |
| Status | Recruiting |
| Started | February 1, 2026 |
| Main results expected | February 1, 2026 |
| Study ends | August 1, 2027 |
| Registry record updated | October 15, 2026 |
| Trial ID | NCT07357012 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men with BPH who need urodynamic testing to evaluate LUTS prior to invasive treatment and can provide informed consent.
✕Probably not a fit
Patients who do not experience improved accuracy, comfort, or convenience from wearable monitoring compared with standard testing.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study tests a lower-abdominal wearable device that uses Electrical Impedance Tomography to monitor bladder function in men with benign prostatic hyperplasia. Participants will wear the device while undergoing traditional uroflowmetry to compare measurements such as maximum and average urine flow rate and voided volume. The goal is to determine agreement between the wearable’s data and the standard test, with additional exploration of dynamic bladder volume tracking and AI-based analysis. The study is conducted at a single center and aims to assess feasibility, accuracy, and potential for at-home monitoring. Eligibility focuses on patients requiring urodynamic evaluation prior to invasive treatment, with several safety-related exclusions to reduce risk.
Why it matters
Potential benefit: If successful, this device could offer a comfortable, non-invasive way to monitor bladder function over time, potentially enabling home or continuous monitoring for BPH patients.
How similar studies have gone: Previous work in similar non-invasive wearable EIT approaches has shown promise but remains relatively early-stage and requires further validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with BPH who need urodynamic tests to further evaluate the underlying pathophysiology of LUTS prior to invasive treatment. Patients who understand and agree with the written informed consent, and voluntary to participate in the study. Exclusion Criteria: Patients with catheter-dependent urinary retention. Patients who cannot void \> 150ml. Patients with uncontrolled acute urinary tract infections. Patients who suffer from severe mental illness or other diseases that may affect judgment or cooperation during the study. Patients with implanted cardiac pacemaker or other electronic implants that may potentially be interfered by the EIT device. Patients with other conditions who are deemed unsuitable for participation by the investigator.
Where it's running
-
Peking University Third Hospital
Beijing, HaiDian, China Recruiting -
Peking University Third Hospital
Beijing, China Not yet recruiting
Study contacts
- Principal investigator: Liu Zhuo — Peking University Third Hospital
- Study coordinator: Lin Xiushi
- Email: 2511110553@bjmu.edu.cn
- Phone: +086 15600338549
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sonablate HIFU Registry for Prostate Cancer and BPH
This registry collects real-world data from men treated with Sonablate HIFU to see how well it works and how it affects urinary and sexual function over the long term.
-
Tamsulosin alone vs. tamsulosin with tadalafil for troublesome urinary symptoms from enlarged prostate
This study tests whether adding tadalafil to tamsulosin helps men with BPH see better urinary symptoms and quality of life, using two tadalafil doses over 12 weeks.
-
MRI-DTI look at the urethral sphincter ring and prostate base shape
This imaging study tests how the male urethral internal sphincter ring appears on MRI-DTI and how it relates to prostate base morphology in men undergoing clinically indicated MRI.
-
Tamsulosin With or Without Tadalafil for a Trial Without Catheter After Acute Urinary Retention
This study tests whether adding tadalafil to tamsulosin helps men with a first episode of acute urinary retention due to enlarged prostate pass urine without needing a catheter.
-
Tamsulosin dose change or switch to silodosin before catheter removal in men with BPH-related acute urinary retention
This trial tests whether continuing tamsulosin, increasing its dose, or switching to silodosin helps men with BPH-related acute urinary retention go without a catheter after seven days.
-
Water Vapor Therapy vs Ejaculation-Sparing Enucleation for Benign Prostatic Hyperplasia
This study tests whether Water Vapor Thermal Therapy (Rezum) or an ejaculation-sparing enucleation procedure better helps sexually active men with bothersome BPH symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.